XPATE
10.5.2022 12:15:12 CEST | Business Wire | Press release
xpate , the rapidly-growing simplified cross-border payment solution provider, has announced a significant expansion of its disruptive developer team, with 35 new team members onboard to speed up building services aimed to enhance flexibility and data processing for merchants and acquirers.
The new appointments, with extensive experience at leading ecommerce platforms AliExpress, and enterprise cloud infrastructure builder Mirantis, will bring unrivalled levels of technical agility and creative user-focused design strengths to xpate.
The company’s ambitious growth plans, focused on helping customers to optimise payment flows and lower operational risk, have come to fruition over the last 12 months for the scaling company. The latest wave of developer hires takes xpate’s headcount to 135, from just three employees at the firm’s inception in 2018.
xpate’s momentum has been fuelled by the launch of breakthrough services such as its acquiring platform Links, and its Core Banking Solution (CBS) which speeds up and streamlines integration with various acquiring systems to give clients access to real-time data processing.
Supporting these services is xpate’s development of its own data warehouse, allowing the company to collect and store data in a centralised location to generate more deep analytics and reporting power for clients. Among the elevated service capabilities is the ability to offer businesses automatic reconciliation of third-party transactions, an internal monitoring and incident reporting system, and a customisable payment page for xpate’s merchants.
Mihails “Mike” Safro, CEO of xpate, comments: “The past three years have been something of a whirlwind, in terms of both the success of our product offerings and the growth of our team – specifically developers.
“Since xpate’s inception, we have worked tirelessly to build a company that combines technical ingenuity with a simplified user experience, to empower merchants to capitalise on all the opportunities in cross-border ecommerce. Our people are at the heart of our culture, and as such, we have assembled a diverse team of talented individuals who not only understand the importance of this ethos, but also offer unparalleled expertise and experience across the financial sector.
“While xpate has witnessed an incredible start to the business, we will certainly not be resting on our laurels. We are constantly working on improving our products and services, and look forward to sharing these exciting and ambitious developments with our customers throughout 2022 and beyond.”
These latest additions to the company’s team follow xpate achieving Mastercard principal member status in 2021 – a significant strategic partnership that has allowed xpate to enhance its platform, offer innovative solutions to new clients, bolster its merchant acquiring portfolio, and take advantage of an extended range of products and services to strengthen market offering.
For more information on xpate, go to: www.xpate.com .
###
About xpate
xpate is the payments platform that prioritises simplicity, speed and user experience.
We provide businesses with a single multi-fit solution that unites all of the desired payment methods to cover an extensive range of demands that otherwise require onboarding and integration with multiple partners.
#ENDS#
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510005806/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom